Please assess the completion status of the following clinical trial:

Trial Title: Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM of age 40 years and above~* Fatty liver disease (grade I or more on USG)~* Glycated A1C more than 7.0% but less than 10.0%~* Patient on standard care of T2DM (metformin, sulfonylureas, DPP-4 inhibitors or insulin, in any combination).~Exclusion Criteria:~1. Serum creatinine more than 1.5 mg/dL~2. Pregnancy~3. Participants treated with pioglitazone or vitamin E in the immediate past 6 months~4. Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers, claustrophobia, foreign bodies and implanted medical devices with ferromagnetic properties).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin dose group (Type: ACTIVE_COMPARATOR): Patient Receive Standard of Care with Empagliflozen
- Standard dose group (Type: NO_INTERVENTION): Standard care for Type 2 Diabetes Mellitus upgraded without Empagliflozin

Based on this trial design, predict the completion outcome and termination type (if applicable).